THE CONTENT OF INTERLEYKIN-17A IN PATIENTS WITH ATOPIC DERMATITIS DEPENDING ON THE GENDER AND THE SEVERITY OF THE DISEASE COURSE

The article studies the level of IL-17A in the blood of patients with atopic dermatitis (AD) depending on the sex and the severity of the disease. Materials and methods. The study of the content of IL-17A was conducted in 45 patients with atopic dermatitis. The structure of patients was dominated by women - 25 (56%) who made up Group I. In group II there were 20 men (54%). The mean age of the patients was (22.8 ± 16.6). Studies of the content of IL-17A were performed by solid-phase analysis using a set of reagents IL-17A containing monoclonal antibodies to IL-17A. The results were processed using mathematical statistics using the PSPP package. Research results. The content of IL-17A in the control group of healthy subjects averaged (13.0 ± 8.9) pg / ml (from 1.3 pg/ml to 27.0 pg / ml) (95% CI 9.1– 16.9 pg / ml). In patients with blood pressure, it ranged from 11.3 to 220.6 pg / ml (mean (113.7 ± 60.6) pg / ml), 95% CI was 96.4-130.9 pg / ml). In the study of atopic dermatitis on the SCORAD scale, the severe course was determined in 13 (52%) women with and made (58.4 ± 14.4) points (from 23.1 to 74.1; 95% CI 48.7–68, 1); and in 11 (55%) men with atopic dermatitis - (52.0 ± 17.8) (from 18.7 to 71.8; 95% CI 44.5–59.6), the course of moderate severity was determined in 8 (32 %) of women and made 24,9 ± 6,2 points, and 6 (30%) men and made 23,7 ± 8,4 points. The mild course of the disease was determined in 4 (15%) female patients and amounted to 7.0 ± 1.5 points, in 4 (15%) men this indicator was slightly smaller and amounted to 6.4 ± 3.2 points. analysis of the level of IL-17A, both in women and in men with atopic dermatitis, varied widely enough. In male patients with atopic der-matitis, it ranged from 19.1 pg / ml to 220.6 pg / ml ( on average (113.7 ± 60.6 pg / ml), 95% CI was 96.4 pg / ml - 130.9 pg / ml). With mild atopic dermatitis, the level of IL-17A was (23.0 ± 8.9) pg / ml. At moderate-to-heavy course, it increased to (86.8 ± 48.6) pg / ml, and at severe course reached (113.7 ± 60.6) pg / ml (p <0.001 by t-test). Woman with mild atopic dermatitis, IL-17A level aver-aged (36.0 ± 60.2) pg / ml. At moderate-to-heavy course, it increased to (100.7 ± 49.7) pg / ml, and at severe course reached (179.7 ± 29.3) pg / ml (p <0.001 by t-test). Conclusions. At present, AD is understood as a multifactorial heterogeneous disease, the development of which is due to the combined influence of hereditary factors and the environment IL-17 is considered one of the most important regulators of natural and adaptive immunity in the body, especially manifested in various diseases, including atopic dermatitis. Adequate immune response with immune toler-ance dyscirculation and insufficient study of the role of the proinflammatory cytokine interleukin-17 (IL-17) in these processes in patients with atopic dermatitis need further detailed study. Obtained estimates of the severity of AD on the SCORAD scale indicate that 50% of men who entered the study and 52% of women had a severe course of skin disease. The severity of AD on the SCORAD scale in women was more pronounced than in men. In women, the content of the proinflammatory cytokine IL-17A was significantly higher, especially in severe and moderate severity of the disease than in male patients. In patients with atopic dermatitis during exacerbation of the disease there is a significant increase in the content of the proinflammatory cytokine IL-17A in the serum. The data obtained confirm the pathogenetic significance of autoimmune disorders in AD patients and may be used in the future to optimize treatment and prophylaxis in these patients.